2021
Pan‐cancer analysis of prognostic metastatic phenotypes
Zaorsky NG, Wang X, Garrett SM, Lehrer EJ, Lin C, DeGraff DJ, Spratt DE, Trifiletti DM, Kishan AU, Showalter TN, Park HS, Yang JT, Chinchilli VM, Wang M. Pan‐cancer analysis of prognostic metastatic phenotypes. International Journal Of Cancer 2021, 150: 132-141. PMID: 34287840, PMCID: PMC8595638, DOI: 10.1002/ijc.33744.Peer-Reviewed Original ResearchConceptsLiver/lung metastasisLung metastasesOverall survivalMetastatic cancerConcordance indexCancer stage IV diseaseCox proportional hazards modelMetastatic phenotypeNational Cancer DatabaseStage IV diseaseEnd Results (SEER) databaseAmerican Joint CommitteeLong-term survivorsLatent class analysisProportional hazards modelStage IVANomogram modelResults databaseSurvival outcomesBetter prognosticationCancer DatabasePan-cancer analysisClinical trialsHazards modelJoint Committee
2019
Is Proton Therapy a “Pro” for Breast Cancer? A Comparison of Proton vs. Non-proton Radiotherapy Using the National Cancer Database
Chowdhary M, Lee A, Gao S, Wang D, Barry PN, Diaz R, Bagadiya NR, Park HS, Yu JB, Wilson LD, Moran MS, Higgins SA, Knowlton CA, Patel KR. Is Proton Therapy a “Pro” for Breast Cancer? A Comparison of Proton vs. Non-proton Radiotherapy Using the National Cancer Database. Frontiers In Oncology 2019, 8: 678. PMID: 30693271, PMCID: PMC6339938, DOI: 10.3389/fonc.2018.00678.Peer-Reviewed Original ResearchLymph node irradiationNational Cancer DatabaseOverall survivalMultivariable analysisBreast cancerCancer DatabaseProton radiotherapyNon-metastatic breast cancerCox proportional hazards modelHigher heart dosesN2-N3 diseaseMultivariate logistic analysisProportional hazards modelAcademic facilitiesLogistic regression modelsHeart dosesAdjuvant radiotherapyNode irradiationHazard ratioNode positivityClinical benefitClinical trialsPRT patientsStage 0Hazards model